MA47290A - Combinaison d'un agoniste sélectif de l'il-2rbeta et d'un agoniste de l'il-15 à action prolongée - Google Patents
Combinaison d'un agoniste sélectif de l'il-2rbeta et d'un agoniste de l'il-15 à action prolongéeInfo
- Publication number
- MA47290A MA47290A MA047290A MA47290A MA47290A MA 47290 A MA47290 A MA 47290A MA 047290 A MA047290 A MA 047290A MA 47290 A MA47290 A MA 47290A MA 47290 A MA47290 A MA 47290A
- Authority
- MA
- Morocco
- Prior art keywords
- agonist
- 2rbeta
- selective
- action
- combination
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562239207P | 2015-10-08 | 2015-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47290A true MA47290A (fr) | 2019-11-27 |
Family
ID=57249859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047290A MA47290A (fr) | 2015-10-08 | 2016-10-07 | Combinaison d'un agoniste sélectif de l'il-2rbeta et d'un agoniste de l'il-15 à action prolongée |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12233104B2 (enExample) |
| EP (1) | EP3359182B1 (enExample) |
| JP (3) | JP7407511B2 (enExample) |
| KR (1) | KR102861230B1 (enExample) |
| CN (1) | CN108135978A (enExample) |
| AU (1) | AU2016335860B2 (enExample) |
| IL (1) | IL258456B (enExample) |
| MA (1) | MA47290A (enExample) |
| MX (1) | MX2018004296A (enExample) |
| WO (1) | WO2017062832A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250057110A (ko) | 2017-05-15 | 2025-04-28 | 넥타르 테라퓨틱스 | 지속 작용성 인터류킨-15 수용체 효현제 및 관련 면역요법 조성물 및 방법 |
| WO2020247388A2 (en) | 2019-06-03 | 2020-12-10 | Medikine, Inc. | Il-2alpha receptor subunit binding compounds |
| US20250082777A1 (en) | 2022-01-10 | 2025-03-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4401756A (en) | 1981-04-14 | 1983-08-30 | Immunex Corporation | Process for preparing human interleukin 2 |
| US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| EP0229108B1 (en) | 1985-06-26 | 1990-12-27 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4705848A (en) | 1986-06-02 | 1987-11-10 | International Minerals & Chemical Corp. | Isolation of bioactive, monomeric growth hormone |
| US5078997A (en) | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5153310A (en) | 1989-02-28 | 1992-10-06 | Du Pont Merck Pharmaceutical Company | Il-2 analogs containing n-linked glycosylation sites |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| IE912365A1 (en) | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US6077519A (en) * | 1993-01-29 | 2000-06-20 | University Of Pittsburgh | Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients |
| US6110721A (en) * | 1993-11-12 | 2000-08-29 | Gilead Sciences, Inc. | Polypeptides and coagulation therapy |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5635597A (en) | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US7008624B1 (en) | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
| US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| US6034072A (en) | 1997-02-10 | 2000-03-07 | Genemedicine, Inc. | IL-2 gene expression and delivery systems and uses |
| US6180095B1 (en) | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| CA2323048C (en) | 1998-03-12 | 2006-10-10 | Shearwater Polymers, Inc. | Poly(ethylene glycol) derivatives with proximal reactive groups |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
| US6602498B2 (en) | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| US6689353B1 (en) | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
| MXPA03002278A (es) | 2000-09-14 | 2004-12-03 | Beth Israel Hospital | Modulacion de respuestas de la celula t mediadas por il-2 e il-15. |
| EP2316490A3 (en) | 2000-10-31 | 2012-02-01 | PR Pharmaceuticals, Inc. | Methods and compositions for enhanced delivery of bioactive molecules |
| FR2826365B1 (fr) | 2001-06-20 | 2003-09-26 | Oreal | Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile |
| JP4764630B2 (ja) | 2002-09-09 | 2011-09-07 | ネクター セラピューティックス | 水溶性ポリマーアルカナール |
| RS20050501A (sr) | 2002-12-26 | 2007-08-03 | Mountain View Pharmaceuticals Inc., | Polimerni konjugati citokina,hemokina,faktora rasta, polipeptidnih hormona i njihovih antagonista sa očuvanom aktivnošću vezivanja receptora |
| ATE444984T1 (de) | 2002-12-31 | 2009-10-15 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
| US7910661B2 (en) | 2003-01-06 | 2011-03-22 | Nektar Therapeutics | Thiol-selective water-soluble polymer derivatives |
| WO2004089280A2 (en) | 2003-04-08 | 2004-10-21 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| PT2644206T (pt) | 2003-05-23 | 2019-07-10 | Nektar Therapeutics | Derivados de peg contendo duas cadeias de peg |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
| US7276478B2 (en) | 2003-09-25 | 2007-10-02 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
| US9539337B2 (en) | 2003-12-10 | 2017-01-10 | Nektar Therapeutics | Compositions comprising two different populations of polymer-active agent conjugates |
| US20060057680A1 (en) | 2004-08-11 | 2006-03-16 | Zheng Xin X | Mutant interleukin-15 polypeptides |
| US20060104945A1 (en) | 2004-10-05 | 2006-05-18 | Choi Yong S | Enhancement of B cell proliferation by IL-15 |
| ES2289663T3 (es) | 2005-02-07 | 2008-02-01 | Novartis Vaccines And Diagnostics, Inc. | Preparacion de aldesleucina para uso farmaceutico. |
| JP4560629B2 (ja) | 2005-03-31 | 2010-10-13 | 国立大学法人 筑波大学 | 腫瘍壊死誘導療法の抗腫瘍効果増強剤 |
| US20060257361A1 (en) * | 2005-04-12 | 2006-11-16 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Novel form of interleukin-15, Fc-IL-15, and methods of use |
| EP1891110A2 (en) | 2005-06-07 | 2008-02-27 | Esbatech AG | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha |
| CA2611823C (en) | 2005-06-16 | 2013-07-30 | Nektar Therapeutics Al, Corporation | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| WO2007075534A2 (en) | 2005-12-16 | 2007-07-05 | Nektar Therapeutics Al, Corporation | Polymer conjugates of glp-1 |
| CA2634167C (en) * | 2005-12-21 | 2015-06-16 | Sentoclone Ab | Improved method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer |
| EP2004231A4 (en) | 2006-04-07 | 2013-07-10 | Nektar Therapeutics | CONJUGATES OF ANTI-TNF-ALPHA ANTIBODY |
| CN101104077A (zh) | 2006-07-12 | 2008-01-16 | 北京紫辰医药生物技术研究所 | 重组人白介素-2与聚乙二醇的偶合物 |
| MX2009007145A (es) | 2006-12-27 | 2009-08-27 | Nektar Therapeutics Al Corp | Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable. |
| WO2008082613A2 (en) | 2006-12-27 | 2008-07-10 | Nektar Therapeutics Al, Corporation | Factor ix moiety-polymer conjugates having a releasable linkage |
| CN106046370A (zh) | 2007-02-28 | 2016-10-26 | 塞瑞纳治疗公司 | 聚噁唑啉poz化合物、合成其的方法、以及靶分子‑poz偶联物 |
| LT2237799T (lt) | 2008-02-01 | 2019-07-25 | Ascendis Pharma A/S | Provaistas, apimantis besiskaidantį linkerį |
| KR20090103209A (ko) | 2008-03-27 | 2009-10-01 | (주)한국비엠아이 | 사람 인터루킨-2 동종체 |
| WO2009135031A1 (en) * | 2008-04-30 | 2009-11-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Substituted il-15 |
| WO2009139905A2 (en) | 2008-05-16 | 2009-11-19 | Nektar Therapeutics | Conjugates of a cholinesterase moiety and a polymer |
| WO2010014258A2 (en) | 2008-08-01 | 2010-02-04 | Nektar Therapeutics Al, Corporation | Conjugates having a releasable linkage |
| EP2350118B1 (en) | 2008-09-19 | 2016-03-30 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| JP5775820B2 (ja) | 2008-10-21 | 2015-09-09 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 遊離可能ｐｅｇ試薬を有するプロドラッグｐｅｇタンパク質結合体において活性成分（インビトロ脱ペグ化）を決定する方法 |
| TWI534152B (zh) | 2010-07-30 | 2016-05-21 | 巴克斯特國際公司 | 用於肟連接的親核性催化劑 |
| ES2866674T3 (es) | 2010-11-12 | 2021-10-19 | Nektar Therapeutics | Conjugados de una fracción de IL-2 y un polímero |
| WO2013020079A2 (en) * | 2011-08-04 | 2013-02-07 | Nektar Therapeutics | Conjugates of an il-11 moiety and a polymer |
| WO2014201378A1 (en) | 2013-06-13 | 2014-12-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy |
| PT3134123T (pt) | 2014-02-21 | 2021-03-22 | Nektar Therapeutics India Pvt Ltd | Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1 |
| MA39711A (fr) | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
-
2016
- 2016-10-07 WO PCT/US2016/056088 patent/WO2017062832A1/en not_active Ceased
- 2016-10-07 MA MA047290A patent/MA47290A/fr unknown
- 2016-10-07 US US15/765,207 patent/US12233104B2/en active Active
- 2016-10-07 KR KR1020187011922A patent/KR102861230B1/ko active Active
- 2016-10-07 MX MX2018004296A patent/MX2018004296A/es unknown
- 2016-10-07 AU AU2016335860A patent/AU2016335860B2/en active Active
- 2016-10-07 EP EP16791713.7A patent/EP3359182B1/en active Active
- 2016-10-07 JP JP2018517898A patent/JP7407511B2/ja active Active
- 2016-10-07 CN CN201680058497.XA patent/CN108135978A/zh active Pending
-
2018
- 2018-03-29 IL IL258456A patent/IL258456B/en unknown
-
2021
- 2021-02-04 JP JP2021016606A patent/JP2021066748A/ja not_active Withdrawn
-
2023
- 2023-05-24 JP JP2023085387A patent/JP2023099731A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023099731A (ja) | 2023-07-13 |
| EP3359182A1 (en) | 2018-08-15 |
| WO2017062832A1 (en) | 2017-04-13 |
| IL258456A (en) | 2018-06-28 |
| AU2016335860A1 (en) | 2018-04-12 |
| CA3000211A1 (en) | 2017-04-13 |
| IL258456B (en) | 2021-07-29 |
| HK1253347A1 (en) | 2019-06-14 |
| US12233104B2 (en) | 2025-02-25 |
| JP2021066748A (ja) | 2021-04-30 |
| US20180296645A1 (en) | 2018-10-18 |
| JP7407511B2 (ja) | 2024-01-04 |
| KR20180063184A (ko) | 2018-06-11 |
| KR102861230B1 (ko) | 2025-09-17 |
| MX2018004296A (es) | 2018-08-01 |
| CN108135978A (zh) | 2018-06-08 |
| JP2018530568A (ja) | 2018-10-18 |
| AU2016335860B2 (en) | 2023-08-10 |
| EP3359182B1 (en) | 2023-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL293377A (en) | Hsd17b13 variants and uses thereof | |
| HRP20260186T1 (hr) | Inkretinski analozi i njihova upotreba | |
| PL3661925T3 (pl) | Nowe związki sulfonamidowo karboksyamidowe | |
| EP3516627A4 (en) | AVATAR CREATION AND EDITING | |
| PT3548033T (pt) | Compostos e respectivos métodos de utilização | |
| MA46180A (fr) | Analogues de l'amyline | |
| PT3368534T (pt) | Ditosilato de valbenazina e polimorfos do mesmo | |
| EP3394065A4 (en) | TETRAHYDROPYRANYL-AMINO-PYRROLOPYRIMIDINONE AND METHOD OF USE THEREOF | |
| EP3417408A4 (en) | DETERMINING THE AVAILABILITY OF CONFERENCE ROOMS | |
| EP3303435A4 (en) | HYDROFLUOROLEFINES AND METHOD OF USE THEREOF | |
| EP3250367A4 (en) | ACTIVE CALIBRATION | |
| EP3292429A4 (en) | AIRCRAFT TOWING EDDY AWARENESS | |
| EP3481814A4 (en) | TETRAHYDRONAPHTHYRIDINPENTANAMID integrin antagonists | |
| PL3411021T3 (pl) | Nowe zastosowanie kombinacji sakubitrylu i walsartanu | |
| DK3672948T3 (da) | Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser | |
| PT2948559T (pt) | ¿antagonistas de kv1.3 e métodos de utilização | |
| EP3543553A4 (en) | ROLLER BEARING CAGE AND ROLLER BEARING | |
| EP3417845A4 (en) | ALPHA FORMULATION COMPOSITION AND ALPHA YELLOW COMPOSITION | |
| DK3706699T3 (da) | Badekonstruktion | |
| MA49905A (fr) | Polyesteramines et polyesterquats | |
| EP3717007C0 (en) | ANTAGONISTS OF ILDR2 AND CORRESPONDING ASSOCIATIONS | |
| EP3431808A4 (en) | BUFFER STOPPER | |
| EP3429517A4 (en) | COOLING CHAIN AND DUST | |
| EP3407974A4 (en) | Amlexanox Analogs | |
| EP3314025A4 (en) | APOBEC3B MUTAGENESIS AND IMMUNOTHERAPY |